AISAP Cardio vs prolaio eVO2peak Module
AI Verdict
Choose AISAP Cardio if…
Choose AISAP Cardio if you require immediate, AI-powered point-of-care ultrasound analysis for rapid and comprehensive cardiac diagnostic assessments at the bedside. This tool is ideal for early detection of structural heart disease and heart failure, providing automated measurements and interpretations of key cardiac parameters directly within your existing clinical workflows.
View AISAP Cardio →Choose prolaio eVO2peak Module if…
Choose prolaio eVO2peak Module if your primary need is to longitudinally estimate peak oxygen consumption (eVO2peak) using real-world patient data from FDA-cleared wearable sensors. This solution is best suited for cardiovascular research or ongoing patient management where tracking functional capacity and fitness over time, leveraging remote sensor data, is crucial.
View prolaio eVO2peak Module →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | AISAP Cardio | prolaio eVO2peak Module |
|---|---|---|
| Deployment | Cloud-based | Cloud |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AISAP CardioAISAP Cardio emphasizes rapid, AI-powered cardiac diagnostic assessments directly at the patient's bedside, empowering non-cardiologists for immediate decision-making in acute settings. Its integration into existing clinical workflows, EHR/EMR, and PACS further streamlines the process for clinicians. Prolaio, while offering a patient-friendly app for remote monitoring, processes data from remote sensors and integrates outputs into external systems, representing a different, less immediate clinical workflow.
Clinical Value
AISAP CardioAISAP Cardio provides comprehensive diagnostic assessments and measurements for structural heart disease and heart failure at the bedside, demonstrating high sensitivity and specificity for major valve diseases and improving clinician performance. Prolaio's eVO2peak Module offers an estimation of peak oxygen consumption as an adjunctive aid in clinical evaluation, focusing on functional capacity and longitudinal data, but it is not intended as a primary diagnostic tool.
Pricing & Value
TieBoth AISAP Cardio and prolaio eVO2peak Module do not publicly disclose their pricing information, requiring direct contact for details [cite: A pricing, B pricing]. Without transparent pricing, it is not possible to conduct a head-to-head comparison of their cost-effectiveness or overall value proposition.
Enterprise Readiness
prolaio eVO2peak ModuleProlaio explicitly states that it is HIPAA compliant and has a Business Associate Agreement (BAA) available, which are critical for enterprise adoption in healthcare [cite: B has_baa, B hipaa_compliant]. AISAP Cardio lacks explicit public confirmation of HIPAA compliance and BAA availability, which is a disadvantage in demonstrating enterprise readiness.
Innovation
AISAP CardioAISAP Cardio's innovation lies in its pioneering FDA clearance for comprehensive POCUS diagnosis, enabling non-cardiologists to accurately interpret cardiac conditions from limited views at the bedside. This significantly democratizes advanced cardiac diagnostics and impacts immediate clinical decision-making. While Prolaio's use of real-world wearable sensor data and deep learning for eVO2peak estimation is also innovative for remote monitoring and research, AISAP Cardio's direct impact on diagnostic accessibility is arguably more transformative [cite: 1, B description].
Support & Docs
prolaio eVO2peak ModuleProlaio provides more explicit information regarding documentation, including quick-start guides, mobile app instructions for patients, and mentions 'Always-on support'. Furthermore, its certifications (ISO 13485, MDSAP) imply robust internal documentation and quality management systems. AISAP Cardio lacks readily available public details on its support and documentation resources.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AISAP Cardio | prolaio eVO2peak Module |
|---|---|---|
| Name | AISAP Cardio | prolaio eVO2peak Module |
| Company | Aisap | Prolaio |
| Description | FDA-cleared, AI-powered point-of-care ultrasound (POCUS) software platform that provides rapid, comprehensive cardiac diagnostic assessments and measurements, enabling early detection of structural heart disease and heart failure at the bedside. | FDA-cleared software to estimate peak oxygen consumption using real-world patient data for cardiovascular research and care. |
| Key Features | AI-powered interpretation for early cardiac disease detection, Comprehensive cardiac ultrasound software package, Automated generation of analyses, interpretations, and reports, Assessment of valvular pathologies (mitral, tricuspid, aortic regurgitation, aortic stenosis), Measurement of Left Ventricle Ejection Fraction (LVEF), Measurement of right and left ventricular dimensions, atrial areas, ascending aorta diameter, and IVC diameter, Vendor-agnostic and scalable solution, Integration with existing clinical workflows, EHR/EMR, and PACS | Estimates peak oxygen consumption (eVO2peak), Utilizes demographic data, single-lead ECG, and triaxial accelerometry inputs, Processes data from qualified third-party FDA-cleared wearable medical sensors, Applies a locked deep-learning model for eVO2peak estimation, Provides information as an adjunctive aid in clinical evaluation, Enables high-density, longitudinal data collection, Leverages real-world patient data and insights, Features FDA-cleared software and proprietary algorithms |
Videos
Demos, reviews, and walkthroughs featuring AISAP Cardio and prolaio eVO2peak Module.